NKGen (Nasdaq: NKGN) announces it has been selected as the preferred stalking horse bidder for NKMax Co., Ltd. See press release at link below for details. $NKGN nkgenbiotech.com/nkgen-biotech-…

As we welcome 2025, we extend our heartfelt thanks to our dedicated employees, supportive patients, and visionary investors for their unwavering commitment over the past year in advancing our breakthrough NK cell therapy for Alzheimer's disease. $NKGN

NKGen Biotech [Nasdaq: NKGN] is pleased to announce USFDA grants Fast Track designation for the investigation of troculeucel NK cell therapy for the treatment of moderate Alzheimer’s disease (AD). $NKGN bit.ly/42UkYrm

NKGen Biotech [Nasdaq: NKGN] announces Ph1 troculeucel results in Alzheimer's patients published in the peer-reviewed journal "Alzheimer’s Research & Therapy". For more info, visit bit.ly/4gKQYkF $NKGN

NKGen Biotech [Nasdaq:NKGN] appoints Dr. Anita Fletcher as National PI for the Phase 2a trial of troculeucel in Alzheimer’s. AdventHealth Research Institute, Neuroscience Research in Orlando will be the first East Coast clinical site. $NKGN bit.ly/4gPP0j0

NKGen Biotech [Nasdaq:NKGN] administers first dose of troculeucel to frontotemporal dementia (FTD) patient under FDA-cleared compassionate use program, exploring its potential as a treatment for FTD. $NKGN bit.ly/3F0DB2D

NKGen Biotech [Nasdaq:NKGN] administers first dose of troculeucel to stroke patient under FDA-cleared compassionate use program. Troculeucel potentially offers novel approach to reduce chronic inflammation and long-term effects in stroke patients. $NKGN bit.ly/3QJRkhc

This week is Brain Awareness Week, a global campaign highlighting the importance of brain health. At NKGen, we are committed to advancing treatments for brain diseases like neurodegenerative diseases, stroke and frontotemporal dementia. Together we can make a difference. $NKGN

NKGen Biotech [OTC:NKGN] to present at the 13th Annual Alzheimer’s & Parkinson's Drug Development Summit in Boston, highlighting troculeucel as a potential treatment for neurodegenerative diseases. bit.ly/3DNv3vO $NKGN

NKGen Biotech [OTC:NKGN] to present updated troculeucel data at AD/PD™ 2025 including 3-month cognitive/biomarker results and new 6-month data from the ongoing Phase 1/2a trial in moderate Alzheimer’s disease. $NKGN bit.ly/4iGVToP

Nearly 1M people in the U.S. are living with Parkinson's and ~90K are diagnosed each year, making it the 2nd most common neurodegenerative disease after Alzheimer's. NKGen is developing novel NK cell therapies aimed at improving outcomes for neurodegenerative disease patients.

NKGen [OTC:NKGN] presents new data from Ph 1/2a troculeucel trial in moderate Alzheimer’s at AD/PD™ 2025. After 12 months, the two Ph 1 patients improved from moderate to mild Alzheimer’s disease and showed positive biomarker results. bit.ly/44elAZd $NKGN

NKGen Biotech [OTC:NKGN] to present on troculeucel for Alzheimer’s and Parkinson’s at the 7th China International Biotechnology Conference, April 17, 2025, in Beijing. A key opportunity to globally showcase our promising clinical advancements. $NKGN bit.ly/3EhWlec

Happy Medical Laboratory Professionals Week! NKGen proudly celebrates our amazing lab team whose expertise, precision, and dedication are vital to our mission. Thank you for everything you do to help patients in need. #LabWeek2025 #LabHeroes #nkgenbiotech

NKGen Biotech [OTC:NKGN] announces an oral presentation by CEO Dr. Paul Y. Song on preliminary results of troculeucel in patients with Alzheimer’s disease at the 28th Annual ASGCT Meeting in New Orleans. $NKGN bit.ly/3RSJ52Q

NKGen Biotech [OTC:NKGN] CEO Dr. Paul Y. Song invests $2.65M cash in NKGen – proceeds from a successful biotech business sale – aimed to accelerate Ph2 Alzheimer’s trial and fulfill its public company reporting requirements. $NKGN bit.ly/4iWzlPX

NKGen Biotech [OTC:NKGN] to present at the International Cell & Gene Therapy China Summit, held in Nanjing, China, on May 30, 2025, at 1:30 pm CST. CEO Paul Y. Song, M.D. will discuss the promising use of troculeucel for neurodegenerative diseases. $NKGN bit.ly/3Z7Db1T

June is Alzheimer’s & Brain Awareness Month. At NKGen Biotech, we’re advancing innovative NK cell therapies for neurodegenerative diseases and promoting brain health for all. Support research, join trials, and take steps to protect your brain. #ENDALZ #BrainHealth

NKGen Biotech [OTC:NKGN] activates new sites in Phase 1/2a troculeucel trial in moderate Alzheimer’s. Enrollment now open at Ottawa Memory Clinic (Canada) & AdventHealth Orlando (Florida).  A key step to expand access and accelerate recruitment. $NKGN bit.ly/3G7EKXh

NKGen Biotech [OTC:NKGN] has dosed a mild-stage Alzheimer’s patient with its investigational therapy, troculeucel, under compassionate use, after decline with amyloid-targeting treatment. This may inform future development in early-stage disease. $NKGN bit.ly/4kvW1aA